Sorry the below should have read (caps added to what was missed):
I wouldn't worry about not knowing about it last year, with the focus groups (specialists who will recommend the Brevagen test) identifying a $150m a year market with women who have test negative to the Myriad Genetics test and the potential 1 million women ($500m market) who have a positive mammogram >>> BUT AN INDETERMINATE RESULT FROM BREAST BIOPSY <<<, we could quite possibly see significant value added just for the US potential alone.
report, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
